Oscar Health (NYSE:OSCR) Insider Sells $1,309,123.62 in Stock

Oscar Health, Inc. (NYSE:OSCR) insider Mario Schlosser sold 76,962 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $17.01, for a total value of $1,309,123.62. Following the transaction, the insider owned 350,180 shares in the company, valued at $5,956,561.80. The trade was a 18.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Mario Schlosser also recently made the following trade(s):

• On Wednesday, December 24th, Mario Schlosser sold 38,835 shares of Oscar Health stock. The shares were sold at an average price of $15.00, for a total value of $582,525.00.
• On Tuesday, December 2nd, Mario Schlosser sold 23,965 shares of Oscar Health stock. The shares were sold at an average price of $16.59, for a total transaction of $397,579.35.
• On Tuesday, November 11th, Mario Schlosser sold 286,182 shares of Oscar Health stock. The stock was sold at an average price of $15.27, for a total value of $4,369,999.14.

Oscar Health Price Performance

OSCR stock traded up $0.46 during trading on Thursday, hitting $16.94. The stock had a trading volume of 9,174,684 shares, compared to its average volume of 8,529,888. The stock has a market cap of $4.48 billion, a price-to-earnings ratio of -15.12 and a beta of 1.90. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.92 and a current ratio of 0.92. The company’s 50 day moving average price is $15.83 and its two-hundred day moving average price is $16.98. Oscar Health, Inc. has a 1-year low of $11.20 and a 1-year high of $23.80.

Oscar Health (NYSE:OSCR) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.02. The company had revenue of $2.93 billion during the quarter, compared to the consensus estimate of $3.09 billion. Oscar Health had a negative net margin of 2.16% and a negative return on equity of 21.50%. The company’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.22) EPS. On average, sell-side analysts forecast that Oscar Health, Inc. will post 0.69 EPS for the current fiscal year.

Institutional Investors Weigh In On Oscar Health

A number of hedge funds have recently made changes to their positions in OSCR. Envestnet Asset Management Inc. boosted its position in Oscar Health by 200.9% in the second quarter. Envestnet Asset Management Inc. now owns 30,210 shares of the company’s stock valued at $648,000 after buying an additional 20,171 shares in the last quarter. NewEdge Advisors LLC lifted its stake in shares of Oscar Health by 89.7% in the 1st quarter. NewEdge Advisors LLC now owns 188,058 shares of the company’s stock valued at $2,465,000 after acquiring an additional 88,946 shares during the last quarter. Matauro LLC acquired a new stake in shares of Oscar Health during the 2nd quarter valued at $1,508,000. Kingswood Wealth Advisors LLC bought a new stake in Oscar Health during the 2nd quarter worth $576,000. Finally, Lane Generational LLC bought a new stake in Oscar Health during the 2nd quarter worth $4,800,000. Institutional investors and hedge funds own 75.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on OSCR shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Oscar Health in a research note on Wednesday, October 8th. Stephens started coverage on shares of Oscar Health in a research note on Thursday, December 11th. They set an “equal weight” rating and a $17.00 target price for the company. Zacks Research upgraded shares of Oscar Health from a “strong sell” rating to a “hold” rating in a report on Monday, October 13th. Wall Street Zen cut shares of Oscar Health from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Finally, Wells Fargo & Company decreased their price objective on shares of Oscar Health from $14.00 to $11.00 and set an “underweight” rating for the company in a report on Thursday, November 13th. One research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus target price of $16.29.

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.